Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$973.80 5.80 (0.6%) as of 4:30 Fri 5/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 101.95(B)
Last Volume: 351,356 Avg Vol: 769,142
52 Week Range: $692.45 - $993.35
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 24,729 84,192 120,701 282,978
Total Sell Value $23,631,267 $76,701,012 $107,160,703 $220,505,683
Total People Sold 7 13 15 17
Total Sell Transactions 14 38 55 116
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 2406
  Page 2 of 97  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Yancopoulos George Bd. Co-Chair, President & CSO   •       •      –    2024-02-15 4 OE $399.66 $69,030,474 D/D 172,723 925,209     -
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-14 4 S $937.94 $9,831,727 D/D (10,434) 20,378 -2%     
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-09 4 D $951.68 $23,735,851 D/D (24,941) 30,812     -
   Van Plew Daniel P EVP & General Mgr, Industrial   •       –      –    2024-02-09 4 OE $372.46 $13,382,510 D/D 35,375 47,153     -
   Fenimore Christopher R. SVP Finance & CFO   •       –      –    2024-02-09 4 S $950.49 $4,689,320 D/D (4,919) 14,372 -2%     
   Sing George L Director   –       •      –    2024-02-09 4 S $955.00 $477,500 D/D (500) 26,349 -2%     
   Sing George L Director   –       •      –    2024-02-09 4 OE $413.33 $206,665 D/D 500 26,849     -
   Sing George L Director   –       •      –    2024-02-08 4 S $945.00 $472,500 D/D (500) 26,349 -2%     
   Sing George L Director   –       •      –    2024-02-08 4 OE $413.33 $206,665 D/D 500 26,849     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2024-02-07 4 S $950.00 $950,000 D/D (1,000) 38,543 -3%     
   Stahl Neil EVP Research and Development   •       –      –    2024-02-07 4 S $947.34 $7,637,954 D/D (8,037) 52,019 -3%     
   Pitofsky Jason Vice President, ControllerOffi   •       –      –    2024-02-06 3 IO $0.00 $0 D/D 0 4,204 3%     
   Mccourt Marion EVP Commercial   •       –      –    2024-02-05 4 S $934.71 $934,710 D/D (1,000) 13,789 -3%     
   Stahl Neil EVP Research and Development   •       –      –    2024-02-02 4 D $956.65 $21,728,391 D/D (22,713) 60,056     -
   Stahl Neil EVP Research and Development   •       –      –    2024-02-02 4 OE $399.66 $12,289,545 D/D 30,750 82,769     -
   Landry Robert E EVP Finance CFO   •       –      –    2024-02-02 4 D $956.65 $268,819 D/D (281) 23,693     -
   Landry Robert E EVP Finance CFO   •       –      –    2024-02-02 4 OE $378.98 $151,592 D/D 400 23,974     -
   Ryan Arthur F Director   –       •      –    2024-02-01 4 AS $939.53 $95,422 D/D (100) 18,382 2%     
   Mccourt Marion EVP Commercial   •       –      –    2024-02-01 4 AS $945.61 $258,152 D/D (273) 14,789 2%     
   Landry Robert E EVP Finance CFO   •       –      –    2024-01-31 4 D $953.42 $268,864 D/D (282) 23,574     -
   Landry Robert E EVP Finance CFO   •       –      –    2024-01-31 4 OE $378.98 $151,592 D/D 400 23,856     -
   Bassler Bonnie L Director   –       •      –    2024-01-30 4 AS $959.00 $793,093 D/D (827) 1,382 1%     
   Bassler Bonnie L Director   –       •      –    2024-01-30 4 OE $380.95 $315,046 D/D 827 2,209     -
   Landry Robert E EVP Finance CFO   •       –      –    2024-01-24 4 D $951.26 $334,844 D/D (352) 23,456     -
   Landry Robert E EVP Finance CFO   •       –      –    2024-01-24 4 OE $378.98 $189,490 D/D 500 23,808     -
  2406 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 97
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us